PMV Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
PMVP$1.22-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets
| March 31,2024 (unaudited) | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $47,654 | $37,706 |
| Restricted cash | 822 | 822 |
| Marketable securities, current | 150,285 | 165,351 |
| Prepaid expenses and other current assets | 3,699 | 3,530 |
| Total current assets | 202,460 | 207,409 |
| Property and equipment, net | 10,903 | 10,666 |
| Marketable securities, noncurrent | 15,120 | 25,505 |
| Right-of-use assets | 8,211 | 8,382 |
| Other assets | 182 | 190 |
| Total assets | $236,876 | $252,152 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $859 | $3,237 |
| Accrued expenses | 10,319 | 9,940 |
| Operating lease liabilities, current | 880 | 852 |
| Total current liabilities | 12,058 | 14,029 |
| Operating lease liabilities, noncurrent | 12,142 | 12,434 |
| Total liabilities | 24,200 | 26,463 |
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value, 5,000,000 shares authorized at March 31, 2024 and December 31, 2023. No shares issued or outstanding at March 31, 2024 and December 31, 2023. | — | — |
| Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 51,445,862 and 51,445,862 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively. | — | — |
| Additional paid-in capital | 538,078 | 535,468 |
| Accumulated deficit | (325,273) | (310,003) |
| Accumulated other comprehensive (loss) income | (129) | 224 |
| Total stockholders’ equity | 212,676 | 225,689 |
| Total liabilities and stockholders’ equity | $236,876 | $252,152 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.